Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Variants & evidence
1,224 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR E746_S752delinsD3 | ||||||||
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2566In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2567In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2570In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |
| EGFR E746_S752insV1 | ||||||||
| Erlotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 1 | submitted | EID4232In an in vitro study, a Ba/F3 cell line expressing EGFR E746_S752insV demonstrated increased sensitivity to erlotinib treatment (IC50=25nM), comparable to Ba/F3 cells expressing EGFR L858R (a known se… (full text at CIViC) PMID 17877814 · de Gunst et al., 2007 · Open in CIViC | civic |
| EGFR E746_T751delinsA5 | ||||||||
| Erlotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID4221A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC) PMID 19671843 · Jackman et al., 2009 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4222In a lung adenocarcinoma patient with EGFR E746_T751>A mutation EGFR E746_A751>A was associated with improved response to erlotinib treatment. The patient was treated with erlotinib monotherapy and ac… (full text at CIViC) PMID 17085664 · Balak et al., 2006 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | |||||||
| EGFR E746_T751delinsVA1 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID2860In a study of 585 non-small cell lung cancer patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| EGFR E746_T751>I7 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2527In a study of 585 non-small cell lung cancer patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2528A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| Erlotinib | Lung Non-Small Cell Carcinoma | |||||||
| EGFR E746V5 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2540In a study of 585 non-small cell lung cancer patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2541A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | |||||||
| EGFR E884K1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Resistance | — | submitted | EID3813In a lung adenocarcinoma patient harboring EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitor) and EGFR E884K co-mutations, EGFR E884K was reported to be refractory to erlotini… (full text at CIViC) PMID 16407879 · Choong et al., 2006 · Open in CIViC | civic |
| EGFR EGFRVIII2 | ||||||||
| (oncogenic) | Lung Non-Small Cell CarcinomaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID12820Inducible expression of EGFRvIII in Tet op EGFRvIII; CCSP rtTA transgenic mice produced a clear oncogenic phenotype, with sequential development of atypical adenomatous hyperplasia, adenomas, and ulti… (full text at CIViC) PMID 16672372 · Ji et al., 2006 · Open in CIViC | civic |
| Neratinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID12821Tumors driven by EGFRvIII show clear differential sensitivity to EGFR-targeted therapies. In vivo, treatment with the irreversible EGFR/HER2 inhibitor HKI 272 (neratinib) produced an average 88% reduc… (full text at CIViC) PMID 16672372 · Ji et al., 2006 · Open in CIViC | civic |
| ERBB4 Fusion1 | ||||||||
| Mobocertinib + Osimertinib + Tarloxotinib + Trastuzumab DeruxtecanSequential | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID12373This is a case report of a 58-year-old never-smoker diagnosed with metastatic lung adenocarcinoma. The patient was treated with multiple lines of chemotherapy ((1) carboplatin/pemetrexed, (2)docetaxel… (full text at CIViC) PMID 39637337 · Guimaraes-Young et al., 2024 · Open in CIViC | civic |
| EGFR Exon 18 deletion1 | ||||||||
| Erlotinib + GefitinibSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID6038Among 1,402 EGFR mutations, Del19, L858R, and Ins20 were detected in 40%, 47%, and 4%, respectively. Exon 18 mutations, including G719X, E709X, and Del18, were present in 3.2%. Transfected Ba/F3 cells… (full text at CIViC) PMID 26206867 · Kobayashi et al., 2015 · Open in CIViC | civic |
| EGFR Exon 18 Mutation2 | ||||||||
| Befotertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12782An in vitro study transformed Ba/F3 murine cells (IL-3 dependent lymphocyte model) with one of five uncommon EGFR mutations: Del18 (delE709_T710insD), E709K, G719A, S768I, and L861Q. The response to c… (full text at CIViC) PMID 40940797 · Oiki et al., 2025 · Open in CIViC | civic |
| Firmonertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12781An in vitro study transformed Ba/F3 murine cells (IL-3 dependent lymphocyte model) with one of five uncommon EGFR mutations: Del18 (delE709_T710insD), E709K, G719A, S768I, and L861Q. The response to c… (full text at CIViC) PMID 40940797 · Oiki et al., 2025 · Open in CIViC | civic |
| EGFR Exon 18 Overexpression1 | ||||||||
| Bevacizumab + ErlotinibCombination | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID898Overexpression of EGFR exon 18 (Affymetrix Human Exon 1.0 ST) in tumor or blood samples was associated with tumor shrinkage, independently of EGFR mutational status in NSCLC treated with bevacizumab a… (full text at CIViC) PMID 24039832 · Baty et al., 2013 · Open in CIViC | civic |
| EGFR Exon 19 Deletion20 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID2996Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who h… (full text at CIViC) PMID 23982599 · Dungo et al., 2013 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID880A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 9… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | B | |||||
Data updated 3 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| B |
| Supports Sensitivity Response |
| — |
| submitted |
EID2531EGFR belongs to a family of receptor tyrosine kinases that includes EGFR/erbB-1, Her2/erbB-2, Her3/erbB-3, and Her4/erbB-4. Ligand binding causes receptor homo- or hetero-dimerization, leading to acti… (full text at CIViC) PMID 20966921 · Pao et al., 2010 · Open in CIViC |
| civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | — | submitted | EID2532EGFR belongs to a family of receptor tyrosine kinases that includes EGFR/erbB-1, Her2/erbB-2, Her3/erbB-3, and Her4/erbB-4. PMID 15870435 · Cappuzzo et al., 2005 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | — | submitted | EID2533Mutations in exon 19 or exon 21 of EGFR were found at higher frequencies in of tumors from patients who had a clinically significant response to gefitinib treatment compared with patients who had no c… (full text at CIViC) PMID 15118072 · Green, 2004 · Open in CIViC | civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID4211A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC) PMID 19671843 · Jackman et al., 2009 · Open in CIViC |
| civic |
| Gefitinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID4209Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen lung cancer patients who had shown partial response or clinical imporvement in response to gefitinib. O… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2522In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2523In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2526In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID2535In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC |
| civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2536In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2539In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |
| 4 |
| accepted |
EID981Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364… (full text at CIViC) PMID 24439929 · Wu et al., 2014 · Open in CIViC |
| civic |
| 〃 | Lung Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID983In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemothe… (full text at CIViC) PMID 25589191 · Yang et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID882In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In to… (full text at CIViC) PMID 22452895 · Yang et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID881Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was a… (full text at CIViC) PMID 25862853 · Banno et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID969Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to dir… (full text at CIViC) PMID 26515464 · Hirano et al., 2015 · Open in CIViC | civic |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID13095A patient with stage IVA lung adenocarcinoma harboring an EGFR exon 19 deletion developed acquired resistance to osimertinib without an identified molecular resistance mechanism. The patient subsequen… (full text at CIViC) PMID 40959071 · Fu et al., 2025 · Open in CIViC | civic |
| Anti-PD1 Monoclonal Antibody | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Resistance | 4 | accepted | EID7586In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined. Immune checkpoint… (full text at CIViC) PMID 31086949 · Hastings et al., 2019 · Open in CIViC | civic |
| Anti-PD-L1 Monoclonal Antibody | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Resistance | 4 | accepted | EID7587In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined. Immune checkpoint… (full text at CIViC) PMID 31086949 · Hastings et al., 2019 · Open in CIViC | civic |
| Dacomitinib + ErlotinibSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID4859Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy … (full text at CIViC) PMID 26768165 · Ramalingam et al., 2016 · Open in CIViC | civic |
| Deguelin | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12205Deguelin exhibits a potent inhibitory effect in gefitinib-sensitive HCC827 cells with exon 19 deletion (EGFR E746-A750). Both deguelin and gefitinib significantly suppressed EGFR kinase activity, redu… (full text at CIViC) PMID 32081857 · Gao et al., 2020 · Open in CIViC | civic |
| Erlotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID2995On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epider… (full text at CIViC) PMID 24868098 · Khozin et al., 2014 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID884A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were random… (full text at CIViC) PMID 22285168 · Rosell et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | accepted | EID4766In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 d… (full text at CIViC) PMID 27566387 · Kanemaru et al., 2016 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID166690 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-t… (full text at CIViC) PMID 18509184 · Yang et al., 2008 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID2519In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response… (full text at CIViC) PMID 22370314 · Han et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6184A Japanese Phase III clinical study assessed the noninferiority of gefitinib in comparison to erlotinib in 561 patients with postoperative or recurrent stage IIIB/IV lung adenocarcinoma. Patients were… (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID273Exon 19 deletion has been shown to be correlated with gefitinib response. PMID 16730237 · Ji et al., 2006 · Open in CIViC | civic |
| Erlotinib + GefitinibSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID413NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04). PMID 16818686 · Jackman et al., 2006 · Open in CIViC | civic |